BREVICON 0.5/35 TABLETS (28-DAY PACK) .5 MG
NORETHINDRONE : .5 MG ETHINYL ESTRADIOL : .035 MG · DIN 02187094 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is BREVICON 0.5/35 TABLETS (28-DAY PACK)?
BREVICON 0.5/35 TABLETS (28-DAY PACK) .5 MG contains NORETHINDRONE : .5 MG ETHINYL ESTRADIOL : .035 MG. It is listed in the Health Canada Drug Product Database under DIN 02187094, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Apr-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BREVICON 0.5/35 TABLETS (28-DAY PACK) used for?
BREVICON 0.5/35 and BREVICON 1/35 (norethindrone and ethinyl estradiol) are indicated for: the prevention of pregnancy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02187094 |
|---|---|
| Brand name | BREVICON 0.5/35 TABLETS (28-DAY PACK) |
| Generic / active ingredient | NORETHINDRONE : .5 MG ETHINYL ESTRADIOL : .035 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | .5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03AA05 NORETHISTERONE AND ESTROGEN |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Apr-2006 |
| Original market date | 1996-08-14 00:00:00 |
How is it administered?
One tablet daily at the same time. 21-day pack: 21 days on, 7 days off. 28-day pack: 21 active tablets followed by 7 inactive tablets. Start on Day 1, Day 5, or Sunday.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Available in 21 day dispensers, each containing 21 active tablets. Also available in 28 day dispensers, each containing 21 active and 7 inactive tablets.
Contraindications
History of thromboembolic disorders, cerebrovascular/coronary artery disease, liver disease/tumours, breast/endometrial cancer, undiagnosed vaginal bleeding, pregnancy, smoking over age 35.
Warnings and precautions
Cigarette smoking increases risk of serious cardiovascular effects, especially over age 35. Does not protect against HIV/STDs. Increased risk of VTE, stroke, and MI.
What can be used instead?
Other Canadian products sharing ATC code G03AA05 NORETHISTERONE AND ESTROGEN. 6 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BREVICON 0.5/35 TABLETS (21-DAY PACK) | 0.5 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02187086 |
| BREVICON 1/35 TABLETS (21-DAY PACK) | 1 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02189054 |
| BREVICON 1/35 TABLETS (28-DAY PACK) | 1 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02189062 |
| SELECT 1/35 (21-DAY) | 1.0 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02197502 |
| SELECT 1/35 (28-DAY) | 1.0 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02199297 |
| BREVICON 0.5/35 21 TAB | .035 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00373265 |
| BREVICON 0.5/35 28 TAB | .5 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00373273 |
| BREVICON 1/35 21 TAB | .035 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00531006 |
| BREVICON 1/35 28 TAB | .035 MG | TABLET | SYNTEX INC. | CANCELLED POST MARKET | DIN 00531014 |
| GENERESS | 0.025 MG | TABLET (CHEWABLE) | ALLERGAN INC | CANCELLED PRE MARKET | DIN 02435659 |
Who else supplies NORETHISTERONE AND ESTROGEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NORETHISTERONE AND ESTROGEN appears in 14 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.